- In March 2024, MindMed (U.S.) announced promising results from its Phase 2b clinical trial evaluating MM-120 (lysergide) for the treatment of generalized anxiety disorder (GAD). The study demonstrated significant, durable symptom reduction compared to placebo, marking a critical step forward in psychedelic-based therapy and reinforcing MindMed’s leadership in the clinical psychedelic drug development space
- In February 2024, COMPASS Pathways (U.S./U.K.) expanded its collaboration with the U.S. Department of Veterans Affairs to explore the use of psilocybin therapy for veterans suffering from PTSD. This initiative reflects growing governmental and institutional support for the therapeutic potential of psychedelics in addressing mental health conditions affecting service members
- In January 2024, Cybin Inc. (Canada) received FDA approval to proceed with its Phase 2 clinical trial of CYB003, a deuterated psilocybin analog, for the treatment of major depressive disorder (MDD). The approval signifies continued regulatory momentum in North America for novel psychedelic therapeutics
- In October 2023, MAPS Public Benefit Corporation (U.S.) completed its Phase 3 clinical trials for MDMA-assisted therapy in patients with PTSD. The trials showed statistically significant results, laying the groundwork for a potential FDA New Drug Application (NDA) submission, anticipated in 2025
- In August 2023, Alberta became the first Canadian province to regulate the use of psychedelics for therapeutic purposes under professional supervision. This policy shift enables qualified medical professionals to administer substances such as psilocybin and MDMA, setting a precedent for structured psychedelic-assisted therapy across Canada
